FDA OKs First Treatment for Children With LEMS FDA OKs First Treatment for Children With LEMS

Amifampridine (Ruzurgi) is an oral potassium channel blocker indicated for children and adolescents aged 6 years to less than 17 years with the rare autoimmune disease.FDA Approvals
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Alert Source Type: news